Get the Stockscreener App
20.34
3.56%
0.70
Cullinan Therapeutics Inc stock is traded at $20.34, with a volume of 565.53K.
It is up +3.56% in the last 24 hours and up +14.46% over the past month.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
See More
Previous Close:
$19.64
Open:
$19.31
24h Volume:
565.53K
Relative Volume:
0.57
Market Cap:
$1.31B
Revenue:
-
Net Income/Loss:
$-221.04M
P/E Ratio:
-5.4761
EPS:
-3.7143
Net Cash Flow:
$-178.65M
1W Performance:
+14.72%
1M Performance:
+14.46%
6M Performance:
+75.50%
1Y Performance:
+168.34%
1-Day Range:
$18.58
$20.37
1-Week Range:
$17.30
$21.00
52-Week Range:
$5.68
$21.00
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
20.34 | 1.26B | 0 | -221.04M | -178.65M | -3.7143 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Initiated | Citigroup | Buy |
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Aug-21-25 | Resumed | H.C. Wainwright | Buy |
| Jun-11-25 | Resumed | Stifel | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Assenagon Asset Management S.A. Sells 77,023 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 30,000 Shares - MarketBeat
Cullinan Therapeutics (CGEM) investor group discloses 6,491,123-share position - Stock Titan
Cullinan Therapeutics, Inc.Common Stock (CGEM) Stock Price, News, Quote & History - FinancialContent
Cullinan Therapeutics (CGEM): T. Rowe Price reports 6.2% ownership stake - Stock Titan
CGEM (CGEM) insider to sell 30,000 shares after stock option exercise - Stock Titan
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Op - Benzinga
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up After Analyst Upgrade - MarketBeat
CGEM Maintains Outperform Rating -- Price Target Raised to $42.0 - GuruFocus
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $42.00 - MarketBeat
Cullinan Therapeutics (CGEM) Shares Rise 6% Premarket on Positive Lung Cancer Trial Results - GuruFocus
Show Me The Money: Did You Miss CGEM's Rally? Here's What Comes Next - RTTNews
Cullinan rises on trial win for lung cancer drug (CGEM:NASDAQ) - Seeking Alpha
Cullinan: REZILIENT3 Phase 3 Interim Shows Improved PFS for Zipalertinib + Chemo - TradingView
Cullinan Therapeutics, Inc. $CGEM Shares Bought by The Manufacturers Life Insurance Company - MarketBeat
Cullinan Therapeutics Says Phase 3 Trial of Experimental Lung Cancer Drug Met Primary Endpoint - Yahoo Finance
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Report Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial in First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - marketscreener.com
Zipalertinib trial meets primary endpoint in lung cancer study - Investing.com Nigeria
Zipalertinib trial meets primary endpoint in lung cancer study By Investing.com - Investing.com Australia
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer - marketscreener.com
HC Wainwright Issues Pessimistic Outlook for CGEM Earnings - MarketBeat
Biotech Stocks At 52-Week HighsALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH - RTTNews
Cullinan Oncology stock hits 52-week high at 19.43 USD By Investing.com - Investing.com UK
Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 52-Week HighStill a Buy? - MarketBeat
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Cullinan Oncology stock hits 52-week high at 19.43 USD - Investing.com
Cullinan Therapeutics (CGEM) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Dimensional Fund Advisors LP Has $12.87 Million Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cullinan Therapeutics (NASDAQ:CGEM) Issues Quarterly Earnings Results - MarketBeat
Cullinan Therapeutics (CGEM): State Street discloses 3.67M-share, 6% ownership stake - Stock Titan
The Bull Case For Cullinan Therapeutics (CGEM) Could Change Following FDA-Backed Phase 2 CLN-049 Trial - Yahoo Finance
Renaissance Technologies LLC Sells 307,595 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat
JonesTrading Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Cullinan Therapeutics, Inc. Stock 12‑Month Price Target Raised to $33, Implies 87% Upside - TradingView
Cullinan Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cullinan Therapeutics Q2 net loss narrows - TradingView
Cullinan Therapeutics 3Q 2026: Revenue $0 Net loss $53.7M, EPS $(0.81) — 10-Q Summary - TradingView
Cullinan Therapeutics: Q2 Earnings Snapshot - Barchart.com
CGEM: Pipeline advances and strong cash position support growth and late-stage clinical milestones - TradingView
Cullinan Therapeutics reports Q2 2026 net loss of $53.7M, cash and investments $356.0M - TradingView
BRIEF-Cullinan Therapeutics Q2 Operating Income USD -57.254 Million Vs. IBES Estimate USD -57.1 Million - TradingView
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Yahoo! Finance Canada
Cullinan Therapeutics (CGEM) Earnings Date and Reports 2026 - MarketBeat
Cullinan Oncology earnings up next: Can pipeline justify cash burn? By Investing.com - Investing.com UK
CGEM|Cullinan Therapeutics Inc|Price:16.260|Chg%:-0.240 - tradingkey.com
Cullinan Therapeutics (CGEM) Slides 5.8% as Pipeline-Focused Biotech Faces Key Support Test at $15.67Unusual Put Volume - dars.gov.et
Cullinan Therapeutics (CGEM) Pulls Back 5.8% to $16.50 as Biotech Risk-Off Mood WeighsDividend ETF - dars.gov.et
Cullinan Therapeutics (NASDAQ:CGEM) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):